(Q54397597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Antonio Bertolotto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Simona Malucchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Marzia Caldano

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Arianna Sala

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Marco Capobianco

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Alessia di Sapio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Letizia Granieri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

12 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

895-903

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-010-5844-5

18 January 2020

exact match

0 references

cites work

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Development of biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Antibodies to IFN-beta: the Danish National IFN-beta Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5844-5

Quantitation of neutralization of interferon by antibody

21 January 2018

1 reference

12 December 2020

Predictive markers for response to interferon therapy in patients with multiple sclerosis

1 reference

12 December 2020

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

1 reference

12 December 2020

MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

1 reference

12 December 2020

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1 reference

12 December 2020

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies

1 reference

12 December 2020

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

1 reference

12 December 2020

Functional classification of interferon-stimulated genes identified using microarrays

1 reference

12 December 2020

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta

1 reference

12 December 2020

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

12 December 2020

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.

1 reference

12 December 2020

Mechanisms for regulation of cellular responsiveness to human IFN-beta1a

1 reference

12 December 2020

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

12 December 2020

Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

1 reference

12 December 2020

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

1 reference

12 December 2020

10.1007/S00415-010-5844-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21153733%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference